Tom O'Connor
Managing Associate
Tom is a Managing Associate in our Corporate Finance team, specialising in capital markets transactions - including public company IPOs, secondary issues, mergers and acquisitions and general corporate advisory matters.
Awards and Recognition
Biography
Languages - English
Jurisdiction(s) - Queensland, Australia
Tom advises clients on a wide range of corporate finance transactions, including public company IPOs and secondary issues — acting for both issuers and banks — as well as private and public company acquisitions and general company law matters. He has experience working with UK, Australian, and international clients across sectors such as mining and exploration, healthcare, life sciences, and technology.
Experience
-
Cavendish
“Advising Cavendish in its role as nominated adviser, bookrunner and broker to MHA plc on MHA plc's initial public offering on the AIM market of the London Stock Exchange” -
Dr. Falk Pharma GmbH
“Advising Dr Falk on the successful acquisition of Kynos Therapeutics Ltd in a complex, cross-border transaction” -
Novacyt S.A.
“Advising Novacyt on the successful acquisition of Yourgene Health plc by recommended takeover in a Takeover Code governed transaction effected by a court-sanctioned scheme of arrangement”
-
Liberum Capital
“Advising Liberum Capital on its merger with Panmure Gordon to create the UK's largest independent investment bank” Stephenson Harwood advises Liberum on Panmure Gordon merger
新闻与见解
Reframing AIM: Proposed changes to the AIM Rules
Stephenson Harwood advises Augmentum on £185.7 million takeover
Stephenson Harwood advises on two AIM IPOs in a week, signalling renewed momentum for London listings
Stephenson Harwood advises KR1 plc on migration to the Main Market of the LSE
Stephenson Harwood advises Cavendish on MHA plc's London IPO
Shaping the future of AIM: LSE releases discussion paper on changes to the AIM Rulebooks
Stephenson Harwood advises Dr. Falk on acquisition of Kynos Therapeutics